Drug Delivery Systems: The Industrial View

  • K. Yokoyama
  • Y. Ueda
  • A. Kikukawa
  • K. Yamanouchi
Part of the NATO ASI Series book series (NSSA, volume 199)


One of the striking features of lipid emulsion particles is chylomicron-like behavior in the circulation (Davis et al, 1985), i.e., high affinity to capillary walls, especially when the latter are inflamed (Shaw et al, 1979). This had led us to consider drug targeting against the walls of blood vessels and hence to pursue the development of lipid microsphere (fat emulsion) incorporating active substances. We have also become interested in adriamycin-macromolecule conjugates that are expected to increase the selectivity for tumor cells.


Lewis Lung Carcinoma Lx10 Cell Drug Delivery System BDF1 Mouse Dexamethasone Phosphate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Davis, S.S., Hadgraft, J. and Palin, K.J., 1985, Fharmaceutical emulsions,in: “Encyclopedia of Emulsion Technology”, P. Becher, ed.. Dekker, New York.Google Scholar
  2. Dillman, R.O., Shawler, D.L., Johnson, D.E., Meyer, D.L., Koziol, J.A. and Frincke, J.M., 1986, Preclinical trials with canbination and conjugates of T1O1 monoclonal antibody and doxorubicin,Cancer Res., 46:4886.PubMedGoogle Scholar
  3. Esumi, Y., Mitsugi, K., Sekine, S., Yokoshima, T., Kawano, Y., Suzuki, A. and Suwa, T.,1986, Absorption, distribution, metabolism and excretion of %-Lipo PGEl,Kiso to Mnshou, 20:161.Google Scholar
  4. Hamano, T., Sintome, M. and Watanabe, M., 1986, Vasodilation activity of Lipo-PGEl,Kiso to Rinshou, 20:93.Google Scholar
  5. Hoshi, K., Mizushima, Y., Shiokawa, Y., Kageyama, T., Honma, M.,Kashiwazaki, K., Tsunematsu, T. and Kaneko, K., 1985, Double-blind study with liposteroid in rheumatoid arthritis.Drug Exptl.Clin.Res., XI:621.Google Scholar
  6. Ii, S., Okamoto, H., Yokoyama, K. and Suyama, T., 1988, Comparative pharmacokinetic study of dexamethasone palmitate and dexamethasone di- sodium phosphate in chronic rheumatoid arthritis patients,Yakuri to Chiryou, 16:865.Google Scholar
  7. Iwai, K., Maeda, H. and Konno, T., 1984, Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and x- ray image.Cancer Res., 44:2115.PubMedGoogle Scholar
  8. Johnson, D.A. and Laguzza, B.C., 1987, Antitumor xenograft activity with a conjugate of Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PFl/D,Cancer Res., 47:3118.PubMedGoogle Scholar
  9. Kaneko, K., 1985, Studies on liposteroid therapy for rheumatoid arthritis,Ensho, 5:241.CrossRefGoogle Scholar
  10. Manabe, Y., Tsubota, T., Haruta, Y., Kataoka, K., Okazaki, M., Haisa, S., Nakamura, K. and Kimura, I., 1985, Production of a monoclonal antibody-mi tomycin C conjugate, utilizing dextran T-40 and its biological activity,Biochem.Pharmacol., 34:289.PubMedCrossRefGoogle Scholar
  11. Martin, M.F.R., 1980, Prostaglandin Ei in the treatment of systemic sclerosis,Ann.Rheum.Dis., 39:44.Google Scholar
  12. Miura, K., Kumon, S. and Yamao, F., 1982, Phase I study of dexamethasone palmitate incorporated in a fat emulsion (Liposteroid),Kiso to Rinshou, 16:5928.Google Scholar
  13. Mizushima, Y., Hamano, T. and Yokoyama, K., 1982, Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsions,Ann.Rheum.Dis., 41:263.PubMedCrossRefGoogle Scholar
  14. Mizushima, Y., Yanagawa, A. and Hoshi, K., 1983, Prostaglandin is more effective when incorporated in lipid microspheres for treatment of peripheral vascular diseases in man,J.Pharm.Pharmacol., 35:666.PubMedCrossRefGoogle Scholar
  15. Momma, K., 1984, Prostaglandin E1treatment of ductus dependent infants with congenital heart disease,Intern.Angiol., 3(Suppl.):33.Google Scholar
  16. Nakura, K., Hamano, T., Sintome, M. and Watanabe, M., 1986, Location of lipo PGEl in blood vessel,Kiso to Rinshou, 20:143.Google Scholar
  17. Ohyanagi, H., Ishida, H., Ishida, T., Soyama, N., Yamamoto, M., Okumiira, S., Kano, Y., Ueda, Y. and Saitoh, Y., 1988, A monoclonal antibody, KMO 10 reactive with human gastrointestinal cancer and its application for immunotherapy,Jpn.J.Cancer Res.(Gaiin), 79:1349.CrossRefGoogle Scholar
  18. Okamoto, H., Watanabe, M., Ohyanagi, H. and Saitoh, Y., 1985,In vitrohydrolysis of dexainethasone-21-palniitate,Ensho, 5:219.CrossRefGoogle Scholar
  19. Otomo, S., Mizushima, Y., Aihara, H., Yokoyama, K., Watanabe, M. and Yanagawa, A., 1985, Prostaglandin Ei incorporated in lipid microspheres (Lipo PGEl),Drugs Exptl.Clin.Res., X:627.Google Scholar
  20. Pimm, M.V., 1988, Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations,Crit.Rev.Ther.Drug Carrier Syst., 5:189.PubMedGoogle Scholar
  21. Shaw, I.H., Knight, C.G., Thomas, D.P.P., Phillips, N.C. and Dingle, J.T., 1979, Liposome-incorporated corticosteroids: 1. The interaction of liposomal Cortisol palmitate with inflammatory synovial membrane,Br.J.Exp.Pathol., 38:553.Google Scholar
  22. Sugai, T., Okamoto, H. and Yokoyama, K., 1984, Vasoconstrictor activity and percutaneous absorption of dexamethasone-21-palmitate, a main component of “Liposteroid”,Hifu, 26:525.Google Scholar
  23. Tavoloni, N. and Guarino, A.M., 1980, Disposition and metabolism of adria- mycin in rats.Pharmacology, 21:244.PubMedCrossRefGoogle Scholar
  24. Tomlinson, E., 1986, (Patho)physiology and the temporal and spatial aspects of drug delivery,in: “Site-specific Drug Delivery”, E. Tomlinson and S.S. Davis, eds., John Wiley and Sons Ltd., Chichester.Google Scholar
  25. Tsukada, Y., Hurwitz, E., Kashi, R., Sela, M., Hibi, N., Hara, A. and Hirai, H., 1982, Chemotherapy by intravenous administration of conjugates of daunomycin with monoclonal and conventional anti-rat -fetoprotein antibodies,Proc.Nat1.Acad.Sei.USA, 79:7896.CrossRefGoogle Scholar
  26. Tsukada, Y., Ohkawa, K. and Hibi, N., 1987, Therapeutic effect of treatment with polyclonal or monoclonal antibodies to -fetoprotein that have been conjugated to daunomycin via a dextran bridge: studies with an-fetoprotein-producing rat hepatoma tumor model.Cancer Res., 47:4293.PubMedGoogle Scholar
  27. Ueda, Y., Muntechika, K., Kikukawa A., Kano, Y., Yamanouchi, K. and Yokoyama, K., 1989, Comparison of efficacy, toxicity and pharmacokinetics of free adriamycin and adriamycin linked to oxidized dextran in rats,Chem.Pharm.Bull., 37:1639.PubMedCrossRefGoogle Scholar
  28. Yokoyama, K., Okamoto, H., Watanabe, M., Suyama, T. and Mizushima, Y., 1985, Development of a corticosteroid incorporated in lipid microspheres (Liposteroid),Drug Exptl.Clin.Res., X:611.Google Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • K. Yokoyama
    • 1
  • Y. Ueda
    • 1
  • A. Kikukawa
    • 1
  • K. Yamanouchi
    • 1
  1. 1.Research DivisionGreen Cross CorporationHirakata 572Japan

Personalised recommendations